| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6369062 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6503911 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6617328 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6525057 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6479496 | MENARINI INTL | Methods for treating angina with ranolazine |
May, 2019
(4 years ago) | |
| US6562826 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6864258 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6852724 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
| US6303607 | MENARINI INTL | Method for administering a sustained release ranolanolazine formulation |
May, 2019
(4 years ago) | |
| US6620814 | MENARINI INTL | Sustained release ranolazine formulations |
May, 2019
(4 years ago) | |
Ranexa is owned by Menarini Intl.
Ranexa contains Ranolazine.
Ranexa has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Ranexa are:
- US6369062
- US6503911
- US6617328
- US6525057
- US6479496
- US6562826
- US6864258
- US6852724
- US6303607
- US6620814
Ranexa was authorised for market use on 12 February, 2007.
Ranexa is available in tablet, extended release;oral dosage forms.
Ranexa can be used as treating chronic angina by administering an extended release form of ranolazine.
The generics of Ranexa are possible to be released after 27 May, 2019.
Drugs and Companies using RANOLAZINE ingredient
Market Authorisation Date: 12 February, 2007
Treatment: Treating chronic angina by administering an extended release form of ranolazine
Dosage: TABLET, EXTENDED RELEASE;ORAL
RANEXA family patents
